Halberd Corp. Develops Second Covid-19 Antibody for Enhanced Nasal Spray and Doubles Performance of New Class of Antibody
Jackson Center, PA, November 5, 2020 – Halberd Corporation (OTC PINK: "HALB") reports its research team developed a second monoclonal antibody against Covid-19 SARS 2 disease antigens paving the way for development of a potentially more effective nasal spray. Additionally, Halberd’s continuing work on its new class of antibody doubles the performance capacity of a ...